Menu
Not yet recruiting NCT06596213

Hepatitis Inequalities Study

Observational Chronic Hepatitis B HEPATITIS C VIRUS CHRONIC INFECTION

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Chronic Hepatitis B, HEPATITIS C VIRUS CHRONIC INFECTION. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Overcoming Inequalities in Health to Eliminate Hepatitis - Real-World Evidence from a Territory-Wide Cohort

Overview

Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.

Primary outcome measures

  • Safety [Time frame: From 1 January 2000 to 31 March 2024]
Secondary outcome measures (1)
  • Safety [Time frame: From 1 January 2000 to 31 March 2024]

Eligibility criteria

Inclusion criteria

  • Patients will be eligible if they have any of these viral markers (HBeAg / HBsAg / HBV DNA / HCV RNA) and/or any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.

Exclusion criteria

  • Patients with missing age, gender, ethnicity and socioeconomic status
  • (Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status
  • Serious medical illnesses or malignancy with life expectancy \<1 year

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061. PMID 22537432

Identifiers

NCT: NCT06596213 · CRE2024.361

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗